| abstract |
There is a need for HGF modulators that can be used as therapeutic agents and diagnostic agents. Part of the invention is based on the discovery of a group of binding proteins that specifically bind HGF, particularly human HGF. These binding proteins are antibody systems as long as they contain the CDR-based antigen (ie, HGF) binding sites of a group of antibodies that specifically bind HGF. The above problems have been solved by providing a group of binding proteins that bind hepatocyte growth factor (HGF), particularly human HGF, and neutralize its activity. These binding proteins can be used as diagnostic agents and / or therapeutic agents. In terms of therapeutic activity, these binding proteins can be used to treat certain HGF-responsive diseases, such as certain HGF-responsive tumors. [Selection figure] None |